Humacyte, Inc. (HUMA) Financials
Annual revenue, profitability and per-share results for Humacyte, Inc., as reported in SEC filings.
Revenue • FY2025
$2.04M
Net income • FY2025
-$40.83M
▲ 72.5%YoY
Gross margin • FY2025
-376.1%
Diluted EPS • FY2025
-$0.26
▲ 79.4%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $2.04M | -$40.83M | -$7.66M | -$0.26 | -$105.93M | -5306.0% | — |
| FY2024 | $0 | -$148.7M | — | -$1.26 | -$99.69M | — | — |
| FY2023 | $0 | -$110.78M | — | -$1.07 | -$75.58M | — | — |
| FY2022 | $0 | -$11.96M | — | -$0.12 | -$72.18M | — | — |
Figures as reported in Humacyte, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a HUMA filing.
Get an email when HUMA files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.